1. Home
  2. PBYI vs BFAC Comparison

PBYI vs BFAC Comparison

Compare PBYI & BFAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • BFAC
  • Stock Information
  • Founded
  • PBYI 2010
  • BFAC 2021
  • Country
  • PBYI United States
  • BFAC United States
  • Employees
  • PBYI N/A
  • BFAC N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • BFAC Blank Checks
  • Sector
  • PBYI Health Care
  • BFAC Finance
  • Exchange
  • PBYI Nasdaq
  • BFAC Nasdaq
  • Market Cap
  • PBYI 153.2M
  • BFAC 152.7M
  • IPO Year
  • PBYI N/A
  • BFAC 2021
  • Fundamental
  • Price
  • PBYI $2.92
  • BFAC $11.14
  • Analyst Decision
  • PBYI Strong Buy
  • BFAC
  • Analyst Count
  • PBYI 1
  • BFAC 0
  • Target Price
  • PBYI $7.00
  • BFAC N/A
  • AVG Volume (30 Days)
  • PBYI 416.5K
  • BFAC 4.3K
  • Earning Date
  • PBYI 11-07-2024
  • BFAC 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • BFAC N/A
  • EPS Growth
  • PBYI 492.79
  • BFAC 49.83
  • EPS
  • PBYI 0.47
  • BFAC 0.37
  • Revenue
  • PBYI $243,569,000.00
  • BFAC N/A
  • Revenue This Year
  • PBYI N/A
  • BFAC N/A
  • Revenue Next Year
  • PBYI N/A
  • BFAC N/A
  • P/E Ratio
  • PBYI $6.26
  • BFAC $29.86
  • Revenue Growth
  • PBYI 6.30
  • BFAC N/A
  • 52 Week Low
  • PBYI $2.23
  • BFAC $10.84
  • 52 Week High
  • PBYI $7.73
  • BFAC $11.55
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 47.45
  • BFAC 55.51
  • Support Level
  • PBYI $2.82
  • BFAC $11.13
  • Resistance Level
  • PBYI $3.12
  • BFAC $11.15
  • Average True Range (ATR)
  • PBYI 0.20
  • BFAC 0.00
  • MACD
  • PBYI -0.03
  • BFAC 0.00
  • Stochastic Oscillator
  • PBYI 14.71
  • BFAC 75.00

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About BFAC Battery Future Acquisition Corp.

Battery Future Acquisition Corp is a blank check company.

Share on Social Networks: